| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BRACHY.2011.07.005 |
| P698 | PubMed publication ID | 22265434 |
| P50 | author | Brian J. Davis | Q37381917 |
| Louis Potters | Q40327316 | ||
| Michael J Zelefsky | Q51936867 | ||
| P2093 | author name string | Anthony L Zietman | |
| Richard G Stock | |||
| Eric M Horwitz | |||
| Gregory S Merrick | |||
| Wayne M Butler | |||
| W Robert Lee | |||
| American Brachytherapy Society | |||
| Juanita M Crook | |||
| Nelson N Stone | |||
| Peter D Grimm | |||
| P433 | issue | 1 | |
| P304 | page(s) | 6-19 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Brachytherapy | Q1823269 |
| P1476 | title | American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy | |
| P478 | volume | 11 |
| Q55094112 | A cold spot compensation technique using a combination of trans-rectal ultrasonography and intraoperative computed tomography for interstitial permanent prostate brachytherapy: a single-arm prospective trial. |
| Q90446626 | A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate 125I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial |
| Q50959718 | A novel greedy heuristic-based approach to intraoperative planning for permanent prostate brachytherapy. |
| Q93387657 | Acute and late toxicities in localized prostate cancer patients treated with low-dose 125I brachytherapy (110 Gy) in combination with external beam radiation therapy versus brachytherapy alone (160 Gy) |
| Q39041614 | Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning |
| Q39006967 | American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review. |
| Q30403952 | An image-guidance system for dynamic dose calculation in prostate brachytherapy using ultrasound and fluoroscopy. |
| Q42576691 | Assessment of I-125 seed implant accuracy when using the live-planning technique for low dose rate prostate brachytherapy |
| Q43440505 | CCAFU Recommendations 2013: Prostate cancer |
| Q54941097 | COMP report: CPQR technical quality control guidelines for low-dose-rate permanent seed brachytherapy. |
| Q38106699 | Canadian prostate brachytherapy in 2012. |
| Q85258724 | Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer |
| Q39116395 | Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow. |
| Q41192354 | Combination of 5α-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB. |
| Q85886949 | Comparing CTVs for permanent prostate brachytherapy |
| Q34008499 | Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. |
| Q90027680 | Comparison of multiparametric MRI-based and transrectal ultrasound-based preplans with intraoperative ultrasound-based planning for low dose rate interstitial prostate seed implantation |
| Q38848137 | Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer |
| Q36276830 | Comparison of permanent (125)I seeds implants with two different techniques in 500 cases of prostate cancer |
| Q92382604 | Comparison of pre-implant treatment planning and post-implant dosimetry in I-125 spinal metastases brachytherapy |
| Q41689121 | Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy |
| Q57110410 | Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience |
| Q49545205 | Current status of brachytherapy in cancer treatment - short overview |
| Q104568219 | Development and Preliminary Evaluation of an Anthropomorphic Trans-rectal Ultrasound Prostate Brachytherapy Training Phantom |
| Q36048698 | Difference in the rate of rectal complications following prostate brachytherapy based on the prostate-rectum distance and the prostate longitudinal length among early prostate cancer patients |
| Q46969507 | Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning. |
| Q39023961 | Dosimetry of permanent interstitial prostate brachytherapy for an interoperative procedure, using O-arm based CT and TRUS. |
| Q41115701 | Evaluation of the dosimetric impact of loss and displacement of seeds in prostate low-dose-rate brachytherapy |
| Q38196711 | Evaluation of time, attendance of medical staff, and resources during interstitial brachytherapy for prostate cancer : DEGRO-QUIRO trial |
| Q34795596 | Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer |
| Q55312114 | Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. |
| Q30403949 | Feasibility of vibro-acoustography with a quasi-2D ultrasound array transducer for detection and localizing of permanent prostate brachytherapy seeds: a pilot ex vivo study |
| Q58779737 | Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease |
| Q38139392 | Focal low-dose rate brachytherapy for the treatment of prostate cancer. |
| Q41689116 | Focal therapy for prostate cancer: the technical challenges. |
| Q36017399 | High Intensity Focused Ultrasound versus Brachytherapy for the Treatment of Localized Prostate Cancer: A Matched-Pair Analysis. |
| Q54495625 | Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. |
| Q91983389 | Interobserver variability of 3.0-tesla and 1.5-tesla magnetic resonance imaging/computed tomography fusion image-based post-implant dosimetry of prostate brachytherapy |
| Q35582296 | Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment |
| Q55168591 | Late seed migration after prostate brachytherapy with Iod-125 permanent implants. |
| Q30418747 | Light in and sound out: emerging translational strategies for photoacoustic imaging |
| Q55432654 | Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer. |
| Q42761259 | Long-term outcome of early stage prostate cancer treated with brachytherapy analysis after a mean follow-up of 7 years |
| Q89429107 | Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer |
| Q90541519 | Low dose rate prostate brachytherapy |
| Q39029985 | Multisector dosimetry in the immediate post-implant period: significant under dosage of the prostate base |
| Q94564019 | Oligorecurrence Non-small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography-Guided 125I Seed Implantation vs. Second-Line Chemotherapy |
| Q28075914 | Optical fibre sensors: their role in in vivo dosimetry for prostate cancer radiotherapy |
| Q26775800 | Performance and suitability assessment of a real-time 3D electromagnetic needle tracking system for interstitial brachytherapy |
| Q52872938 | Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer: An interim analysis of 312 cases. |
| Q55427963 | Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers. |
| Q55371986 | Permanent prostate brachytherapy pubic arch evaluation with diagnostic magnetic resonance imaging. |
| Q64101793 | Porous Silicon as a Platform for Radiation Theranostics Together with a Novel RIB-Based Radiolanthanoid |
| Q93387663 | Predicting pubic arch interference in permanent prostate brachytherapy based on the specific parameters derived from nuclear magnetic resonance imaging |
| Q37424419 | Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression |
| Q50139190 | Proof of Principle for Local Delivery of a c-Met Inhibitor |
| Q40126200 | Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection |
| Q92862010 | Prostate brachytherapy procedural training: incorporation of related procedures in resident training and competency assessment |
| Q36555616 | Prostate cancer brachytherapy: guidelines overview |
| Q30355910 | Prostate deformation from inflatable rectal probe cover and dosimetric effects in prostate seed implant brachytherapy. |
| Q41097227 | Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure? |
| Q40636362 | Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer. |
| Q33918003 | Radiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy. |
| Q90731152 | Radiation-related Adverse Effects of CT-guided Implantation of 125I Seeds for Thoracic Recurrent and/or Metastatic Malignancy |
| Q37365032 | Re-implantation after insufficient primary 125-i permanent prostate brachytherapy |
| Q27027841 | Recent developments and best practice in brachytherapy treatment planning |
| Q41966741 | Rectal ulcer associated with SpaceOAR hydrogel insertion during prostate brachytherapy |
| Q43177782 | Reduced dose to urethra and rectum with the use of variable needle spacing in prostate brachytherapy: a potential role for robotic technology |
| Q38018733 | Results of a surgically derived nomogram to predict Gleason score upgrading applied to a cohort of patients with "favorable-risk" prostate cancer treated with permanent seed brachytherapy |
| Q26800257 | Review of advanced catheter technologies in radiation oncology brachytherapy procedures |
| Q41914001 | Safety and efficacy of salvage low-dose-rate brachytherapy for prostate bed recurrences following radical prostatectomy. |
| Q47142647 | Shape analysis of the prostate: establishing imaging specifications for the design of a transurethral imaging device for prostate brachytherapy guidance |
| Q41097961 | Stenting of the Portal Vein Combined with Different Numbers of Iodine-125 Seed Strands: Dosimetric Analyses |
| Q38177470 | Target ablation--image-guided therapy in prostate cancer |
| Q41082788 | Technical and dosimetric aspects of iodine-125 seed reimplantation in suboptimal prostate implants |
| Q91800465 | The current state of randomized clinical trial evidence for prostate brachytherapy |
| Q38700678 | The evolution of brachytherapy for prostate cancer |
| Q37424415 | The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy |
| Q36680127 | The impact of trainee involvement on outcomes in low-dose-rate brachytherapy for prostate cancer. |
| Q37001892 | The phylogeny of permanent prostate brachytherapy. |
| Q57112397 | The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer |
| Q33704921 | The use of trans-applicator intracavitary ultrasonography in brachytherapy for cervical cancer: phantom study of a novel approach to 3D image-guided brachytherapy |
| Q36310669 | Three-dimensional verification of ¹²⁵I seed stability after permanent implantation in the parotid gland and periparotid region |
| Q38152713 | Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer: the DEGRO-QUIRO trial |
| Q52606123 | Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer. |
| Q26738622 | Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizers |
| Q92354835 | Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers |
| Q36849125 | Two solutions for registration of ultrasound to MRI for image-guided prostate interventions |
| Q64911399 | UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016. |
| Q30448749 | Ultrasound-fluoroscopy registration for prostate brachytherapy dosimetry |
| Q48553280 | Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy. |
| Q34669234 | Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series. |
Search more.